Physician profile
Chase A Devalk
NPI 1891316089
$334.12
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.42 · 2022: $182 · 2023: $55.80 · 2024: $19.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endologix LLC | $39.68 | 2021-2022 | |
| Angiodynamics, INC. | $38.90 | 2022 | |
| Shockwave Medical, INC | $32.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.76 | 2021 | |
| Cordis US Corp. | $28.95 | 2022 | |
| Terumo Medical Corporation | $28.69 | 2023 | Azur Cx Detachable |
| W. L. Gore & Associates, INC. | $26.93 | 2021 | |
| Ge Healthcare | $20.66 | 2022 | |
| Tactile Systems Technology INC | $20.05 | 2022 | |
| Lemaitre Vascular, INC. | $19.32 | 2024 | Xenosure Biologic Patch |
| Boston Scientific Corporation | $19.23 | 2022 | |
| Silk Road Medical, INC. | $13.74 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Bard Peripheral Vascular, INC. | $13.37 | 2023 | Venovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Devalk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.